Solid Biosciences Inc. Finance Lease, Right-of-Use Asset, Amortization
Solid Biosciences Inc. (SLDB) reported Finance Lease, Right-of-Use Asset, Amortization of $441.00 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:FinanceLeaseRightOfUseAssetAmortization · last filed 2025-03-06
- Solid Biosciences Inc. finance lease, right-of-use asset, amortization for the quarter ending 2019-03-31 was $52.00K.
- Solid Biosciences Inc. finance lease, right-of-use asset, amortization for fiscal 2024 was $441.00K, a 7.35% decline from fiscal 2023.
- Solid Biosciences Inc. finance lease, right-of-use asset, amortization for fiscal 2023 was $476.00K.
| Period end | Finance Lease, Right-of-Use Asset, Amortization 3 month | Finance Lease, Right-of-Use Asset, Amortization 12 month |
|---|---|---|
| 2024-12-31 | $441.00K 10-K · filed 2025-03-06 | |
| 2023-12-31 | $476.00K 10-K · filed 2025-03-06 | |
| 2019-03-31 | $52.00K 10-Q · filed 2019-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |